The first time Lyell CEO Rick Klausner looked at what PACT Pharma was trying to accomplish with neoantigens, non-viral T cell engineering and cancer, he felt they couldnt get it done. But in the 3 years since theyve launched, Klausner has become a believer.<\/p>\n
Now, hes a believer and a partner.<\/p>\n
Early Thursday morning, Klausner and PACT CEO Alex Franzusoff announced a plan to jointly pursue one of the Holy Grails of oncology R&D. Blending their technologies and bringing a wide network of leading experts to the table, the two companies are working on a personalized T cell therapy for solid tumors. And an IND is in the offing.<\/p>\n
The collaboration joins the Lyell team, which has been concentrating on overcoming the exhaustion that afflicts the first generation of cell therapies, with a PACT group that has developed tech to identify a patients unique signature of cancer mutations and use a non-viral method to engineer their T cells into cancer therapies.<\/p>\n
I spent some time on Wednesday talking with Klausner and Franzusoff about the deal, which comes with an undisclosed set of financials as Lyell invests in the alliance.<\/p>\n
Unlock this article along with other benefits by subscribing to one of our paid plans. <\/p>\n
SUBSCRIBE SIGN IN <\/p>\n
<\/p>\n
Read the original:<\/p>\n
What's this? A rival bidder heads back to the table with a better offer for Tetraphase. Antibiotics show faint signs of life - Endpoints News<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" The first time Lyell CEO Rick Klausner looked at what PACT Pharma was trying to accomplish with neoantigens, non-viral T cell engineering and cancer, he felt they couldnt get it done. Continue reading